GlaxoSmithKline Deals One-Two Punch With BRAF/MEK Pair

GSK presented Phase III results for its BRAF inhibitor dabrafenib and its MEK inhibitor trametinib at the American Society of Clinical Oncology annual meeting June 4. But the real excitement is over the just-starting Phase III trial combining the two drugs.